Estradiol/mesoprogestin - Schering
Alternative Names: Mesoprogestin/estradiol - ScheringLatest Information Update: 12 Jul 2006
At a glance
- Originator Bayer Schering Pharma
- Class
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Menopausal syndrome
Most Recent Events
- 12 Jul 2006 No development reported - Phase-II for Menopausal syndrome in Europe (PO)
- 08 Aug 2001 New profile
- 08 Aug 2001 Phase-II clinical trials for Menopausal syndrome in Europe (PO)